Neurocrine Biosciences, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$80Mgeneral payments (2019-2025)
$5.8Mresearch payments (2019-2025)
63,567clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $7.2M
2020 $3.0M
2021 $7.7M
2022 $14M
2023 $15M
2024 $14M
2025 $20M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Psychiatry $33M
Neurology (Psychiatry & Neurology) $16M
Psychiatric/Mental Health (Nurse Practitioner) $14M
Medical Oncology $3.4M
Physician Assistant $2.9M
Family $2.0M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Stephen Sherwin San Francisco, CA Medical Oncology $3,379,695.25
Rakesh Jain Lake Jackson, TX Psychiatry $738,708.56
Mark Reynolds Durham, NC Psychiatry $720,002.01
Cherian Karunapuzha Oklahoma City, OK Neurology (Psychiatry & Neurology) $703,004.29
Amita Patel Dayton, OH Psychiatry $700,182.54
Richard Trosch Farmington Hills, MI Neurology (Psychiatry & Neurology) $665,667.50
Laxman Bahroo Washington, DC Neurology (Psychiatry & Neurology) $657,277.44
Ilan Melnick Coral Gables, FL Psychiatry $654,604.79
Maria Ospina Phoenix, AZ Neurology (Psychiatry & Neurology) $642,958.04
Amy Lacouture Baton Rouge, LA Psychiatric/Mental Health (Nurse Practitioner) $634,714.22

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.